بررسي عوارض خوني داروي ميتوكسانترون در درمان بيماران مبتلا به مولتيپل اسكلروزيس ثانويه پيشرونده

Evaluation of hematoligic side effects of mitoxantrone in patients with secondary progressive form of multiple sclerosis

Multiple sclerosis (MS) is one of the most common neurologic discovered in young adult. Several new drugs have been introduced for the treatment of multiple sclerosis. Among these, mitoxantrone a drug with immunosuppressant and cytotoxic activity used for various cancers has attached interest. One study has shown as light benefical effect on MS. The aim of this study was to investigated hematologic side effects of mitoxantrone administred in Patients with secondaiy progressive multiple sclerosis (SP-MS).This descriptive study was done in neurological clinical Aria Hospital of Mashhad in 2003-2006.15 Patients with Secondary Progressive Multiple Sclerosis (SP-MS) who had no history of cardiac and hepatic disorders or- Immuno suppressant use were included. They were administered 12mg/m2 mitoxantrone intravenously every 3 month for 8 infusions. Before starting the treatment CBC count was measured and it was 2 weeks after each drug infusion. Individual characteristics, result of lab, history of medical collected by questionnaire and analyzed by descriptive statistics and frequency tables.From 15 patients with SP-MS were included 8 female and 9 male. This drug led to the 38ʹ/. reduction in WBC count and 17.57. reduction in platelets count in different sub types of leukocyte, neutrophils showed the reduction in number (46/.) Among the 15 patients studied no one under went thrombocytopenia. The effect of this drug on hemoglobin was not statistically significant.The finding of this study showed hematologic side effects of mitoxantrone administered in patients with SP-MS. WBC count should be checked before each infusion and if there was rise of this tests the infusion should be stopped for 2-6 month.